^
HER-2 L755S
|
Breast Cancer
|
HER-2 L755S
|
Breast Cancer
|
neratinib Resistant: D – Preclinical
Cancer Res - 3 days (New D)
|
neratinib Resistant: D – Preclinical
Cancer Res - 3 days - (New D)
|
HER-2 G778_P780dup
|
Breast Cancer
|
HER-2 G778_P780dup
|
Breast Cancer
|
HM 78136B Sensitive: D – Preclinical
Cancer Res - 3 days (New D)
|
HM 78136B Sensitive: D – Preclinical
Cancer Res - 3 days - (New D)
|
HER-2 L755S
|
Breast Cancer
|
HER-2 L755S
|
Breast Cancer
|
HM 78136B Sensitive: D – Preclinical
Cancer Res - 3 days (New D)
|
HM 78136B Sensitive: D – Preclinical
Cancer Res - 3 days - (New D)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
trastuzumab + pertuzumab Sensitive: A1 - Approval
Anticancer Drugs - 6 days (New A1)
|
trastuzumab + pertuzumab Sensitive: A1 - Approval
Anticancer Drugs - 6 days - (New C3)
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
abemaciclib Sensitive: A1 - Approval
Precision Oncology News - 1 week (New A1)
|
abemaciclib Sensitive: A1 - Approval
Precision Oncology News - 1 week - (New A2)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
trastuzumab + pyrotinib Sensitive: B - Late Trials
Clin Cancer Res - 1 week (New B)
|
trastuzumab + pyrotinib Sensitive: B - Late Trials
Clin Cancer Res - 1 week - (New C3)
|
TMB-H
|
Triple Negative Breast Cancer
|
TMB-H
|
Triple Negative Breast Cancer
|
durvalumab Sensitive: C3 – Early Trials
Clin Cancer Res - 1 week (New C3)
|
durvalumab Sensitive: C3 – Early Trials
Clin Cancer Res - 1 week - (New C3)
|
No biomarker
|
Triple Negative Breast Cancer
|
No biomarker
|
Triple Negative Breast Cancer
|
sacituzumab govitecan-hziy Sensitive: A1 - Approval
Everest Medicines Press Release - 2 weeks (New A1)
|
sacituzumab govitecan-hziy Sensitive: A1 - Approval
Everest Medicines Press Release - 2 weeks - (New A1)
|
BRCA2 mutation + HR positive
|
HER2 Negative Breast Cancer
|
BRCA2 mutation + HR positive
|
HER2 Negative Breast Cancer
|
olaparib Sensitive: A2 - Guideline
Medicine (Baltimore) - 2 weeks (New A2)
|
olaparib Sensitive: A2 - Guideline
Medicine (Baltimore) - 2 weeks - (New C4)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
CNS Oncol - 2 weeks (New A1)
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
CNS Oncol - 2 weeks - (New C4)
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ABSK091 Sensitive: C3 – Early Trials
Nat Commun - 2 weeks (New C3)
|
ABSK091 Sensitive: C3 – Early Trials
Nat Commun - 2 weeks - (New C3)
|
RB1 deletion
|
Estrogen Receptor Positive Breast Cancer
|
RB1 deletion
|
Estrogen Receptor Positive Breast Cancer
|
IGM-9427 Sensitive: D – Preclinical
Oncogene - 2 weeks (New D)
|
IGM-9427 Sensitive: D – Preclinical
Oncogene - 2 weeks - (New D)
|
RB1 deletion
|
Estrogen Receptor Positive Breast Cancer
|
RB1 deletion
|
Estrogen Receptor Positive Breast Cancer
|
WEE1 inhibitor + Aurora kinase inhibitor Sensitive: D – Preclinical
Oncogene - 2 weeks (New D)
|
WEE1 inhibitor + Aurora kinase inhibitor Sensitive: D – Preclinical
Oncogene - 2 weeks - (New D)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
trastuzumab + abemaciclib Sensitive: A2 - Guideline
ASCO.org - 3 weeks (New A2)
|
trastuzumab + abemaciclib Sensitive: A2 - Guideline
ASCO.org - 3 weeks - (New A2)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
trastuzumab + lapatinib Sensitive: A2 - Guideline
ASCO.org - 3 weeks (New A2)
|
trastuzumab + lapatinib Sensitive: A2 - Guideline
ASCO.org - 3 weeks - (New A2)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
trastuzumab + tucatinib Sensitive: A1 - Approval
ASCO.org - 3 weeks (New A1)
|
trastuzumab + tucatinib Sensitive: A1 - Approval
ASCO.org - 3 weeks - (New A2)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
margetuximab Sensitive: A1 - Approval
ASCO.org - 3 weeks (New A1)
|
margetuximab Sensitive: A1 - Approval
ASCO.org - 3 weeks - (New A2)
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
palbociclib Sensitive: A1 - Approval
Mol Clin Oncol - 3 weeks (New A1)
|
palbociclib Sensitive: A1 - Approval
Mol Clin Oncol - 3 weeks - (New C3)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
lapatinib Sensitive: A2 - Guideline
ASCO.org - 3 weeks (New A2)
|
lapatinib Sensitive: A2 - Guideline
ASCO.org - 3 weeks - (New A2)
|
HER-2 underexpression
|
Breast Cancer
|
HER-2 underexpression
|
Breast Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials
N Engl J Med - 3 weeks (New B)
|
fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials
N Engl J Med - 3 weeks - (New B)
|
ER positive
|
HER2 Negative Breast Cancer
|
ER positive
|
HER2 Negative Breast Cancer
|
AZD5363 Sensitive: C3 – Early Trials
Lancet Oncol - 3 weeks (New C3)
|
AZD5363 Sensitive: C3 – Early Trials
Lancet Oncol - 3 weeks - (New C3)
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval
|
docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Sensitive: A1 - Approval
|
ado-trastuzumab emtansine Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
TAC Sensitive: A1 - Approval
|
TAC Sensitive: A1 - Approval
|
HR positive
|
HER2 Positive Breast Cancer
|
HR positive
|
HER2 Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
ribociclib Sensitive: A1 - Approval
|
ribociclib Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval
|
pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive: A1 - Approval
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
alpelisib Sensitive: A1 - Approval
|
alpelisib Sensitive: A1 - Approval
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
pegylated liposomal doxorubicin Sensitive: A1 - Approval
|
pegylated liposomal doxorubicin Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
ribociclib Sensitive: A1 - Approval
|
ribociclib Sensitive: A1 - Approval
|
ER negative
|
Breast Cancer
|
ER negative
|
Breast Cancer
|
toremifene Resistant: A1 - Approval
|
toremifene Resistant: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
toremifene Sensitive: A1 - Approval
|
toremifene Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
albumin-bound paclitaxel Sensitive: A1 - Approval
|
albumin-bound paclitaxel Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
lapatinib Sensitive: A1 - Approval
|
lapatinib Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Negative Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Negative Breast Cancer
|
trastuzumab + lapatinib Sensitive: A1 - Approval
|
trastuzumab + lapatinib Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
lapatinib Sensitive: A1 - Approval
|
lapatinib Sensitive: A1 - Approval
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
everolimus Sensitive: A1 - Approval
|
everolimus Sensitive: A1 - Approval
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
talazoparib Sensitive: A1 - Approval
|
talazoparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
talazoparib Sensitive: A1 - Approval
|
talazoparib Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
docetaxel + doxorubicin hydrochloride Sensitive: A1 - Approval
|
docetaxel + doxorubicin hydrochloride Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
docetaxel Sensitive: A1 - Approval
|
docetaxel Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
docetaxel + capecitabine Sensitive: A1 - Approval
|
docetaxel + capecitabine Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
capecitabine Sensitive: A1 - Approval
|
capecitabine Sensitive: A1 - Approval
|
HR positive
|
HER2 Positive Breast Cancer
|
HR positive
|
HER2 Positive Breast Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
fulvestrant Sensitive: A1 - Approval
|
fulvestrant Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
eribulin mesylate Sensitive: A1 - Approval
|
eribulin mesylate Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
non-pegylated liposomal doxorubicin Sensitive: A1 - Approval
|
non-pegylated liposomal doxorubicin Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
trastuzumab/hyaluronidase-oysk Sensitive: A1 - Approval
|
trastuzumab / hyaluronidase-oysk Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
bevacizumab Sensitive: A1 - Approval
|
bevacizumab Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
exemestane Sensitive: A1 - Approval
|
exemestane Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
exemestane Sensitive: A1 - Approval
|
exemestane Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
letrozole Sensitive: A1 - Approval
|
letrozole Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
letrozole Sensitive: A1 - Approval
|
letrozole Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
anastrozole Sensitive: A1 - Approval
|
anastrozole Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
anastrozole Sensitive: A1 - Approval
|
anastrozole Sensitive: A1 - Approval
|
ER negative
|
Breast Cancer
|
ER negative
|
Breast Cancer
|
anastrozole Sensitive: A1 - Approval
|
anastrozole Sensitive: A1 - Approval
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
toremifene Sensitive: A1 - Approval
|
toremifene Sensitive: A1 - Approval
|
HER-2 amplification
|
Breast Cancer
|
HER-2 amplification
|
Breast Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
ixabepilone Sensitive: A1 - Approval
|
ixabepilone Sensitive: A1 - Approval
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
talazoparib Sensitive: A1 - Approval
|
talazoparib Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
fulvestrant Sensitive: A1 - Approval
|
fulvestrant Sensitive: A1 - Approval
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
fulvestrant Sensitive: A1 - Approval
|
fulvestrant Sensitive: A1 - Approval
|
No biomarker
|
Triple Negative Breast Cancer
|
No biomarker
|
Triple Negative Breast Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
leuprolide acetate for depot suspension Sensitive: A1 - Approval
|
leuprolide acetate for depot suspension Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
trastuzumab + docetaxel Sensitive: A1 - Approval
|
trastuzumab + docetaxel Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
TCHP Sensitive: A2 - Guideline
|
TCHP Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
CaT Sensitive: A2 - Guideline
|
CaT Sensitive: A2 - Guideline
|
ER positive
|
HER2 Positive Breast Cancer
|
ER positive
|
HER2 Positive Breast Cancer
|
trastuzumab + lapatinib Sensitive: A2 - Guideline
|
trastuzumab + lapatinib Sensitive: A2 - Guideline
|
